Induced neurons (iNs), the product of somatic cells directly converted to neurons, are a way to obtain patient-derived neurons from tissue that is easily accessible. Through this route, mature neurons can be obtained in a matter of a few weeks. Here, we describe a straightforward and rapid one-step protocol to obtain iNs from dermal fibroblasts obtained through biopsy samples from adult human donors. We explain each step of the process, including the maintenance of the dermal fibroblasts, the freezing procedure to build a stock of the cell line, seeding of the cells for reprogramming, as well as the culture conditions during the conversion process. In addition, we describe the preparation of glass coverslips for electrophysiological recordings, long-term coating conditions, and fluorescence activated cell sorting (FACS). We also illustrate examples of the results to be expected. The protocol described here is easy to perform and can be applied to human fibroblasts derived from human skin biopsies from patients with various different diagnoses and ages. This protocol generates a sufficient amount of iNs which can be used for a wide array of biomedical applications, including disease modeling, drug screening, and target validation.
Introduction
Development of efficacious treatments for neurological disorders have been hampered by the limited access to living human brain cells to perform mechanistic studies and functional assays. About a decade ago, this situation radically changed with the development of induced pluripotent stem cell (iPSCs) technology 1, 2 . This, combined with a better understanding of the neural differentiation mechanisms occurring during normal human development, has allowed for the generation of defined and diverse neuronal subtypes from patient and disease specific material. With such material, it is now possible to study intracellular mechanisms underlying neurological diseases and the potential of different compounds to alleviate those pathological features 3 .
While iPSCs have been revolutionary to the field of neuroscience, one major drawback of these cells is that their ageing signature is erased during the reprogramming process in such a way that the rejuvenated neuron does not retain the vulnerability associated with aging 4, 5, 6 . This particular feature of the neurons that are produced may end up being critical for recapitulating many aspects of the intracellular pathogenic cascade, particularly in the case of diseases for which old age is an important risk factor.
Direct neural reprogramming is a technology where a somatic cell is directly converted into an iN without going through a pluripotent intermediate stage. This allows for rapid generation of human neurons in vitro that can be both patient and disease specific. One remarkable characteristic of direct reprogramming is that the starting age of the donor cell is maintained, and with that, its vulnerability to ageing processes such as increased production of oxidative stress 4, 7 . As a result, iNs from patients with neurological diseases associated with ageing, such as Alzheimer's and Parkinson's disease, are well suited for a broad range of biomedical applications including disease modeling, drug screening assays, and toxicology studies.
The main caveat that has prevented iNs from patients with neurodegenerative disorders being widely used is that they are not easy to reprogram, and this becomes even more difficult with expansion of the fibroblasts. As a result, generation of iN cells in quantities required for these types of applications has not been achieved until only recently 8 . We have now developed a simple method to reprogram fibroblasts from donors of any age in a very efficient manner. This method combines the forced expression of the neuronal transcription factors Ascl1 and Brn2 with a knockdown of the repressor protein RE1-silencing transcription factor (REST) using a single vector. Here, we describe the different steps leading to the generation of iNs converted from skin fibroblasts biopsied from elderly donors.
1. 60 min before plating the aHDFs for reprogramming, coat a 24-well plate with 0.1% gelatin (250 µL/well) and incubate at 37 °C. 2. Aspirate the fibroblast medium on the aHDFs. Wash once with DPBS. Dissociate the cells with 0.05% trypsin (1.5 mL per T75 flask) at 37 °C for 3-5 min. 3. Add fibroblast medium to neutralize the trypsin (3 mL per flush per T75 flask) and collect the detached cells in a 15 mL tube by flushing out the cells in the flask twice. 4. Spin down the cells at 400 x g for 5 min. Discard supernatant, and resuspend the cell pellet in 1 mL of fibroblast medium. 5. Count the cells using an automated cell counter (to ensure a good quality conversion check that the cell viability is above 90% with trypan blue staining). 6. For a complete 24-well plate, prepare a suspension of 1,320,000 cells in 13.2 mL of fibroblast medium to achieve a suspension of 100,000 cells/mL of medium (or 55,000 cells/well in 550 µL of fibroblast medium multiplied by the number of wells needed). 7. Aspirate the gelatin from the plate and wash twice with DPBS. Add 500 µL of the cell suspension to each well and incubate overnight at 37 °C in 5% CO 2 .
Viral Transduction (Day 0)
NOTE: Working with lentiviral particles requires category 2 equipment and the use of an agent to neutralize the virus. Wearing double pairs of gloves is also strongly recommended. ; the construct is available in a plasmid repository. For details on the procedure to produce lentiviruses please refer to reference 9 . 3. Add the necessary volume of lentivirus to infect the aHDFs at multiplicity of infection (MOI) of 20 to the medium without any transduction enhancers.
4. Replace the medium in the 24-well plate with fibroblast medium containing the lentiviral vector (500 µL/well) and incubate overnight at 37 °C in 5% CO 2 . 5. The next day, replace the medium in the wells with fresh fibroblast medium without the lentiviral vector. The medium is considered infectious for 7 days and as such, adequate protection and handling procedures should be used during the first week following viral transduction.
Maintenance of the Converting Cells
NOTE: Once conversion begins cells are susceptible to lifting; take care to tip the plate up and use a 1,000 µL pipette when removing media to avoid cells detaching.
1. On day 3, remove the fibroblast medium and add 500 µL of early neuronal conversion medium (see Table 1 ). 2. Two to three times a week, take out 225 µL of old medium from the well and add-in 250 µL of fresh early neuronal conversion medium. 3. On day 18, remove all of the medium from each well and replace with 500 µL of late neuronal conversion medium (see Table 1 ). 4. Continue to change half of the medium as above with late neuronal conversion medium every 2-3 days until day 25 or experiment endpoint ( Figure 1A) . NOTE: If cells are not plated in every well for the experiment, fill empty wells with PBS or water to prevent overt evaporation of the medium and minimize variation between wells. 8 . This is advantageous because it gives access to both disease and patient specific human iNs from tissue that is easily accessible. Although this protocol is efficient, it will not produce a 100% neuronal yield, and as such a purification step using FACS for instance is required.
Stock Concentration
The most critical step within this protocol is viral transduction (protocol section 4). It is crucial that the virus titer is precise, in addition to having plated an accurate number of aHDFs for conversion. The recommended titer for use with this protocol is between 4 x 10 8 and 4 x 10 9
. Using a titer of anything below 1 x 10 8 would not be recommended as adding large volumes of virus will be toxic to the cells. Moreover, as the fibroblasts begin to covert to iNs they will become more fragile and susceptible to lifting. It is essential to be gentle when changing the media as not to disturb the cells too much. This can be done by removing the fluid slowly with a 1,000 µL pipette. Finally, when plating for reprogramming (protocol section 3) it is important to ensure a healthy fibroblast population before beginning an experiment; this is indicated by a cell viability of above 90% with trypan blue staining. The aHDFs should always be passaged before reaching 95% confluency.
If there is noticeable cell death before viral transduction, do not begin conversion: double check that the cell viability is above 90% and that there were no problems with coating of the plate. It is expected to have a small amount of cell death following viral transduction, however, this should not be significant. In this case, confirm accurate seeding of 50,000 aHDFs/well and check the virus titer. If there is noticeable inconsistency between wells during conversion, first check that every well contains an equal amount of media and overt evaporation is not occurring at the edges (if necessary extra media can be added to the edge wells). Alternatively, check step 4.4, and ensure appropriate mixing for a homogenous suspension when transducing. It is crucial to add the lentivirus to the medium first, before adding this into the wells. Directly adding lentivirus into the wells will increase well to well variability and is also likely to be toxic to the cells. Lastly, always check that the medium is warmed to 37 °C before adding to cells.
This protocol includes optional sections for coating conditions for long term culture of iNs and FACS sorting to increase neuronal purity. For experiments wishing to investigate functional characterization of iNs, a protocol for preparation of glass coverslips for electrophysiology has also been included. The conversion protocol here is set up for use with a 24-well plate; if desired this can be modified to a 6-, 12-, 48-, 96-well plate or flasks. In this case, please adjust all volumes to the surface area of the plate or flask utilized.
This protocol uses the forced expression of Ascl1 and Brn2 in combination with a REST knockdown all packaged in one single vector 8 to generate iNs of a pan-neuronal phenotype. The generation of any glial subtypes with this method, however, has not been assessed. This method would thus need to be modified for use with other reprogramming factors to obtain subtype specific neurons. Direct reprogramming has previously shown the possibility to generate motor neurons, sensory neurons, photoreceptors, striatal medium spiny neurons, and dopaminergic neurons 10, 14 . This will be beneficial when investigating neurological diseases in which specific neuronal subtype are preferentially affected, for example Parkinson's disease and dopaminergic neurons.
Until very recently, direct neural reprogramming technology did not allow for the production of iNs in a standardized and efficient mannerto a level that is required for toxicology and drug screening assays on a large scale. This new method is very efficient and can be used on fibroblasts that have been passaged many times, such that it now removes these restrictions and opens up for a vast array of studies, not only in a human neural system, but also in a system that can be patient specific. The simplicity of this approach renders the iN technology accessible for any groups wanting to perform similar studies in-house and can be easily used not only for large scale biomedical applications, such as drug screening and toxicology assays, but also to support data derived from animal models and human post mortem tissue samples.
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